Neoadjuvant Herceptin in Patients With Breast Cancer

Inclusion Criteria: * All patients must be female. * Informed consent must be signed. * Women with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible. Locally advanced cancers must be of clinical and/or radiologic size \> 4 cm, and/or are deemed surgically inoperable. * Her2/neu overexpressing tumors defined as HercepTest score of 3+, or \>/= one-third of invasive tumor showing membranous staining, or fluorescence in situ hybridization (FISH) positive. * Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential. * Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal. * Performance status (World Health Organization \[WHO\] scale) \< 2 and life expectancy \> 6 months. * Age \> 18. * No metastatic disease without concomitant primary breast cancer. * No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Exclusion Criteria: * Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential. * Severe underlying chronic illness or disease. * Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) \< 50%. * Patients on other investigational drugs while on study. * Severe or uncontrolled hypertension defined as blood pressure (BP) \> 180/100 on three separate occasions. * History of congestive heart failure. * History of coronary arterial disease.